Ask AI
ProCE Banner Activity

Redefining Hepatocellular Carcinoma Treatment in the Immunotherapy Era: Experts Answer Your Questions

Clinical Thought

This commentary provides insights from hepatocellular carcinoma (HCC) experts answering questions from an audience of healthcare professionals during a live webinar exploring the role of immunotherapy in patients with metastatic, intermediate, and high-risk early-stage HCC held during the 2025 ASCO Annual Meeting.

Released: July 11, 2025

Expiration: July 10, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Eisai and Merck Sharp & Dohme LLC.

Eisai

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Joseph W. Franses, MD, PhD: consultant/advisor/speaker: Eisai, Foundation Medicine, Genentech, Guardant Health; researcher: AbbVie, Alnylam, Genentech, Iterion Therapeutics, Omega Therapeutics.

Neehar Parikh, MD, MS: consultant/advisor/speaker: AstraZeneca, Exact Sciences, Exelixis, Fujifilm Medical, Genentech, Sirtex.

Mark Yarchoan, MD: grant (paid to institution): Bristol Myers Squibb, Genentech; consultant/advisor/speaker: AstraZeneca, Exelixis, Incyte, Lantheus; owner: Adventris.